Clinical trial
Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
NCT00476242 · New York State Psychiatric Institute, Other · Completed
Key facts
| NCT number | NCT00476242 |
|---|---|
| Title | Memantine as a Supplement to Naltrexone in Treating Heroin Dependence |
| Official title | Placebo Controlled Study of Memantine as an Adjunct to Naltrexone in the Treatment of Opioid Dependence |
| Acronym | NAMHS |
| Lead sponsor | New York State Psychiatric Institute, Other |
| Collaborators | National Institute on Drug Abuse (NIDA) NIH |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Opioid Dependence, Heroin Dependence |
| Intervention type | Drug |
| Interventions | Vivitrol, memantine |
| Enrollment | 82 |
| Start date | Jun 1, 2008 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | May 21, 2007 |
| Last update posted | Jul 17, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: